KEYNOTE-024
2016
Pembrolizumab in PD-L1–High Advanced NSCLC
In 305 patients with stage IV NSCLC and PD-L1 TPS ≥50%, no EGFR/ALK alterations, pembrolizumab improved progression-free and overall survival compared with platinum-doublet chemotherapy.
Result
Efficacy: BICR-assessed PFSHR 0.5
Below 1 favours pembrolizumab, above 1 favours platinum-doublet chemotherapy.
Event rates Pembrolizumab 10.3 vs platinum-doublet chemotherapy 6.0 months
Also reported: 5-yr OS 31.9% vs 16.3%.
- Subtopic
- NSCLC immunotherapy
- Design
- Open-label RCT
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- Reck M, et al. N Engl J Med. 2016;375(19):1823-1833.doi 10.1056/NEJMoa1606774
Discussion & critique
First single-agent checkpoint-inhibitor approval as first-line therapy in lung cancer. Strict PD-L1-high selection (TPS ≥50%): do not generalise.